Safety Non-Clinical Studies of IMT504, a Non-CpG Oligonucleotide with Pharmacological Action on the Immune and Tissue Repair Systems

MONTANER AD

San Diego

Conferencia; IBC's 17th Annual TIDES (Oligonucletoide and peptide therapeutics. From research through commercialization); 2015

IBC Life Sciences

IMT504 is a non-CpG oligonucleotide with immunomodulatory as well as tissue repair activity. In vivo, IMT504 has proven to be effective in animal models of vaccine potency, tissue regeneration and sepsis. Safety assessment for IMT504, including pharmacodynamics, pharmacokinetics and toxicity studies in rats and monkeys, in a single- or repeated- dose administration by the subcutaneous or intravenous routes is presented. A dose range in which IMT504 can be used safely in clinical trials is suggested.